Alliance for Safe Biologic Medicines Releases 2017 Canadian Prescriber Survey

For Immediate Release ~National survey reveals physician attitudes on key policy issues related to originator biologics and biosimilars ~   Ottawa, Ontario (November 22, 2017) – A new national survey conducted by the Alliance for Safe Biologic Medicines (ASBM) found that Canadian physicians overwhelmingly support distinguishable names for all biologics, including biosimilars. Survey results also […]

CMS Reverses Course on Shared Billing Codes for Biosimilars

On November 2nd, 2017, the Centers for Medicare and Medicaid Services (CMS) issued a final rule for the 2018 Physician Fee Schedule, which governs reimbursement rates for physicians.    In a significant development, beginning in 2018 CMS will update payment for biosimilars. Under the previous rule finalized in 2015 under the Obama Administration, all of the biosimilars sharing one reference […]

ASBM Presents at 65th WHO Naming Meeting

On October 17th, ASBM Chair, Madeline Feldman, M.D., FACR; Advisory Board Chair, Philip Schneider, MS, FASHP; and Executive Director, Michael Reilly, Esq. appeared before the 65th Consultation on International Nonproprietary Names (INN) for Pharmaceutical Substances in Geneva, Switzerland.   ASBM has regularly appeared before the INN Consultation since 2013 and continues to advocate for distinguishable […]

ASBM Supports WHO Naming Plan in Comments to Australia’s TGA

On July 28th, 2017 the Australian Therapeutic Goods Administration (TGA) announced that it was seeking comments from interested parties on the nomenclature for biologic medicines, including biosimilars. In a comment letter dated September 7th, ASBM responded, advocating for distinct naming of all biologics and biosimilars, and urging the TGA to adopt the World Health Organization’s […]

New York Becomes 36th State to Pass Biosimilar Substitution Law

On Monday, October 23rd, Governor Andrew Cuomo signed biosimilars legislation (S.4788A/A.7509A) regarding the pharmacy substitution of interchangeable biosimilar medical products—a measure ASBM and others have pursued in New York over the past two years.   New York is now the 36th state to pass biosimilars substitution legislation.  This law (Chapter 357 of the Laws of 2017) […]

ASBM Meets with Canadian Health Officials in Ottawa

On October 4th, ASBM Executive Director Michael Reilly met with several Canadian health officials in Ottawa to discuss naming and substitution policy, and preview data from ASBM’s Canadian prescriber survey which will be released October 17th at the DIA Canada Annual Meeting in Ottawa. While in Ottawa, Mr. Reilly met with the Minister of Health’s […]

FDA Launches Biosimilar Education Site for Prescribers

On October 23rd, the FDA launched a robust online resource center aimed at at educating prescribers on biosimilars.  The website includes fact sheets which explain regulatory terminology such as “reference product” and “interchangeability”, as well as detailing the biosimilar approval process and how these medicines are prescribed and substituted. Sections include: Biosimilar and Interchangeable Products Biosimilar Development, Review, and […]

ASBM Presents Poster at ESMO 2017

On September 10, 2017 ASBM presented a poster at the European Society of Medical Oncology (ESMO) 2017 Congress which presented perspectives of oncologists from 12 countries regarding biosimilar substitution. Responses were drawn from five recent ASBM surveys which gathered perspectives of more than 1,850 biologic prescribers in Australia, Canada, France, Germany, Italy, Spain, the United Kingdom, and the […]

More News
Behind the Numbers: A Q&A With ASBM’s Michael Reilly

Behind the Numbers: A Q&A With ASBM’s Michael Reilly

  The Alliance for Safe Biologic Medicines conducts regular surveys to better understand physicians’ perspectives on originator biologics and biosimilars. The organization recently released its 2017 Canadian Prescriber Survey. The survey reveals Canadian physicians’ attitudes on a number of critical policy issues surrounding the approval and use of originator biologics and biosimilars.   83 per […]

New Leadership Means New Opportunities for Better Policy

New Leadership Means New Opportunities for Better Policy

By Michael Reilly Executive Director, ASBM Prior to serving as ASBM’s Executive Director, I worked from 2002-2008 at the U.S. Department of Health and Human Services (HHS), including three years as Associate Deputy Secretary under Alex M. Azar, who was nominated recently as HHS Secretary. As a former health regulator, I understand the challenges we face when trying […]

FDA Launches Biosimilar Education Site for Prescribers

FDA Launches Biosimilar Education Site for Prescribers

On October 23rd, the FDA launched a robust online resource center aimed at educating prescribers on biosimilars.  The website includes fact sheets which explain regulatory terminology such as, “reference product” and “interchangeability”.  The fact sheets also detail the biosimilar approval process as well as explain how these medicines are prescribed and substituted.   Sections include: Biosimilar and Interchangeable Products; Biosimilar Development, […]

New York Becomes 36th State to Pass Biosimilar Substitution Law

New York Becomes 36th State to Pass Biosimilar Substitution Law

On Monday, October 23rd, Governor Andrew Cuomo signed biosimilars legislation (S.4788A/A.7509A) regarding the pharmacy substitution of interchangeable biosimilar medical products—a measure ASBM and others have pursued in New York over the past two years.   New York is now the 36th state to pass biosimilars substitution legislation.  This law (Chapter 357 of the Laws of 2017) […]

CMS Reverses Course on Shared Billing Codes for Biosimilars

CMS Reverses Course on Shared Billing Codes for Biosimilars

On November 2nd, 2017, the Centers for Medicare and Medicaid Services (CMS) issued a final rule for the 2018 Physician Fee Schedule, which governs reimbursement rates for physicians.    In a significant development, beginning in 2018 CMS will update payment for biosimilars. Under the previous rule finalized in 2015 under the Obama Administration, all of the biosimilars sharing one reference […]

Biosimilars 101

Biologic medicines are used to treat millions of patients with serious illnesses like cancer, arthritis, and psoriasis. The patents for many biologic therapies are expiring over the coming years, and biosimilars will be entering the marketplace. Regulatory authorities around the world have put policies in place to ensure that biosimilars have been appropriately tested, and are safe and effective for patients.

Member Partners

The Alliance for Safe Biologic Medicines is an organization composed of diverse healthcare groups and individuals—from patients to physicians, biotechnology companies that develop innovative and biosimilar medicines and others who are working together to ensure patient safety is at the forefront of the biosimilars policy discussion.

logo logo logo